Search
Returning search results with filters:
Remove filter for
Audience: Health professionals
Remove filter for
Category: Drugs
Remove filter for
Last updated: 2019
Remove filter for
Type: Alert
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 12 of 12 items.
GILENYA (fingolimod) - Risk of Congenital Malformations
AlertHealth professional risk communication | 2019-12-19
Health Canada evaluating NDMA in metformin drugs
AlertInformation update | 2019-12-05
XELJANZ / XELJANZ XR (tofacitinib) - Risk of Thrombosis
AlertHealth professional risk communication | 2019-12-02
ULORIC ® (febuxostat) - Increased Risk of Cardiovascular Fatal Outcomes
AlertHealth professional risk communication | 2019-11-04
LEMTRADA (alemtuzumab) - Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular Reactions
AlertHealth professional risk communication | 2019-10-15
Health Canada advises Canadians to exercise caution when taking gabapentin or pregabalin with opioids
AlertInformation update | 2019-09-17
Tacrolimus and the Risk of Graft Rejection due to Medication Errors: Inadvertent Switching between Different Oral Formulations
AlertHealth professional risk communication | 2019-07-22
Substance use during summer events and festivals
AlertInformation update | 2019-06-20
ALERTEC (modafinil) and the Risk of Congenital Anomalies
AlertHealth professional risk communication | 2019-06-20
Important Safety Information on ACTEMRA® (tocilizumab) - Risk of Hepatotoxicity
AlertHealth professional risk communication | 2019-05-21
Health Canada is advising Canadians about the potential health risks associated with unauthorized cell therapy treatments such as stem cell therapy
AlertInformation update | 2019-05-15